Company intelligence / Profile preview

Silo Pharma

Englewood Cliffs, New Jersey, USA

Ownership: Private
Development stage: Other

Overview

Silo Pharma is a developmental-stage biopharmaceutical company leveraging both traditional and psychedelic-inspired molecules with novel delivery platforms (intranasal, implant). Lead programs target PTSD (SPC-15) and fibromyalgia/chronic pain (SP-26), both advancing toward IND and Phase 1 in 2025. Preclinical programs include assets for Alzheimer’s (SPC-14, intranasal) and multiple sclerosis (SPU-16, CNS-homing peptide). No clinical results yet; preclinical data show promise in animal models.[1][3][4]

Therapeutic areas: NeurologyRheumatologyPsychiatry
Modalities: Small moleculePsychedelic medicineImplantPeptidesIntranasal formulation
Industry: Biotech

Drug pipeline

1 asset

monobutyrin

Unknown

Partnerships

Columbia UniversityUniversity of Maryland, BaltimoreKymanoxResyca BVWuXi AppTec

Beyond the preview

Go deeper on Silo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silo Pharma.

Explore the full profile